SentiSense Logo

SentiSense

Ctrl+K

55% OFF

Quick tip: Press

K

to search stocks

K

KVUE

Kenvue Inc.

$18.39

+0.14 (+0.77%)

Summary

Stories

News

Metrics

Fundamentals

Drag to measure

Feb 9Feb 12Feb 18Feb 23Feb 26Mar 3Mar 6$17.15$17.90$18.65$20.12

Stock Reports

Upgrade to access stock reports prepared by our team with the help of AI.

What's Included

  • Curated Bull & Bear Case Analysis

  • Data-Driven Investment Perspectives

  • Quantified Risks & Catalysts

  • Expert-Curated Financial Research

Company Profile

Symbol

KVUE


Market Cap

$35.25B


IPO Date

May 4, 2023


CEO

--


Employees

22,000


Sector

--


Industry

PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS


Country

United States


Exchange

--

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.

Read More

Similar Stocks

EL

The Estee Lauder Companies Inc.

$92.72

-3.29%

SentiSense Logo

SentiSense

Sense what the market is doing.

© 2026 Compass AI Data Services, LLC. All rights reserved.


Important Disclaimer: Compass AI Data Services, LLC provides market information, sentiment analysis, and data intelligence. We do not provide investment advice, recommendations, or financial guidance. All information is for informational purposes only. Users are solely responsible for their own investment decisions. Always consult a licensed financial advisor before making investment decisions.

Cookie Preferences

We use cookies to enhance your experience and analyze site traffic. Privacy Policy